SCHEMBL2864582

SCHEMBL2864582

Fc1cc2[nH]nc(-c3ccc4ccccc4c3)c2cc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.47
CDK4 P11802 1/20 0.47
CCNA2 P20248 1/20 0.47
CCND1 P24385 1/20 0.47
CCND3 P30281 1/20 0.47
KDR P35968 1/20 0.47
MAPKAPK2 P49137 2/20 0.45
MAPK9 P45984 2/20 0.44
MAPK8 P45983 1/20 0.44
MAPK10 P53779 1/20 0.44
MAP2K4 P45985 3/20 0.42
DCLK1 O15075 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
CHEK2 O96017 1/20 0.42
CSF1R P07333 1/20 0.42
FER P16591 1/20 0.42
MARK3 P27448 1/20 0.42
FLT4 P35916 1/20 0.42
FLT3 P36888 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2864682 0.83 MAPKAPK2 (0.50) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL19533700 0.81 MAP2K4 (0.47) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL2860960 0.80 CDK4 (0.45) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL4378603 0.80 MAPKAPK2 (0.45) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL2862300 0.79 MEN1 (0.47) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL2863181 0.76 MAPKAPK2 (0.48) CDK2MAPKAPK2MAPK9MAPK10MAP2K4
SCHEMBL13927625 0.76 IDO1 (0.63) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL2863485 0.75 CDK4 (0.46) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL11683287 0.74 CDK2 (0.63) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL11686488 0.74 MAP2K4 (0.63) CDK2MAPKAPK2MAPK9MAPK10MAP2K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CDK2 50/4885CDK4 103/4885CCNA2 398/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 CDK2 154/4885CDK4 165/4885CCNA2 1567/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CDK2 50/4885CDK4 103/4885CCNA2 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.